SLEEP STUDIES AND NEUROCHEMICAL CORRELATES IN PANIC DISORDER AND AGORAPHOBIA

被引:20
|
作者
PECKNOLD, JC
LUTHE, L
机构
[1] Douglas Hospital Research Centre, Verdun, Que.
关键词
5HT-uptake; agoraphobia; generalized anxiety; imipramine binding; panic disorder; sleep studies;
D O I
10.1016/0278-5846(90)90045-I
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although panic disorder is classified by the DSM III among the anxiety disorders, there is evidence from epidemiological and neurochemical studies that links panic to the affective disorders. In addition several of the effective pharmacological treatments suggest, as in the depressive disorders, serotonergic involvement. As part of the evaluation of patients who would take part in the Cross. National Collaborative Panic study, polysomnography, the dexametnasone suppression test and platelet imipramine binding and 5HT-uptake were scheduled. 44 patients who met DSM III criteria on the SCID interview schedule for Panic Disorder consented to enter the study. After being medication free for two weeks, these patients had three consecutive all night polyscmnogranis, followed by a dexamethasone suppression test and platelet study of imipramine binding and 5HT-uptake. In our studies we were unable to find for the panic group as a whole a correlation with reported parameters of sleep architecture in endogenous depression. Similarly the imipramine binding differentiated the panickers from the depressed group. Only the 5HT-uptake was similar in both groups. We also found a subgroup of panickers who resembled depressives in terms of the imipramine binding, 5HT-uptake platelet studies and REM latency. In the analysis of the imipramine and 5HT-uptake over the treatment period, we noted changes which suggest a role for serotonin, certainly in a subgroup of panickers and possibly for the group of panic disorder as a whole. © 1990.
引用
收藏
页码:753 / 758
页数:6
相关论文
共 50 条
  • [41] FAMILIAL ANALYSIS OF PANIC DISORDER AND AGORAPHOBIA
    SMERALDI, E
    JOURNAL OF AFFECTIVE DISORDERS, 1989, 17 (01) : 1 - 8
  • [42] SEROTONIN UPTAKE IN PANIC DISORDER AND AGORAPHOBIA
    PECKNOLD, JC
    SURANYICADOTTE, B
    CHANG, H
    NAIR, NPV
    NEUROPSYCHOPHARMACOLOGY, 1988, 1 (02) : 173 - 176
  • [43] Clinical staging in panic disorder and agoraphobia
    Pavlichenko, A.
    EUROPEAN PSYCHIATRY, 2016, 33 : S326 - S326
  • [44] Treatment of panic disorder with and without agoraphobia
    Baldwin, DS
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S542 - S542
  • [45] TREATMENT OF PANIC DISORDER AND AGORAPHOBIA WITH CLONAZEPAM
    SPIER, SA
    TESAR, GE
    ROSENBAUM, JF
    WOODS, SW
    JOURNAL OF CLINICAL PSYCHIATRY, 1986, 47 (05) : 238 - 242
  • [46] CLONAZEPAM IN THE TREATMENT OF PANIC DISORDER AND AGORAPHOBIA
    POLLACK, MH
    ROSENBAUM, JF
    TESAR, GE
    HERMAN, JB
    SACHS, GS
    PSYCHOPHARMACOLOGY BULLETIN, 1987, 23 (01) : 141 - 144
  • [47] Treatment of panic disorder with and without agoraphobia
    Baldwin, DS
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S328 - S328
  • [48] Lamotrigine Administration in Panic Disorder With Agoraphobia
    Masdrakis, Vasilios G.
    Papadimitriou, George N.
    Oulis, Panagiotis
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (03) : 126 - 128
  • [49] PHARMACOLOGIC TREATMENT OF PANIC DISORDER AND AGORAPHOBIA
    STEWART, RS
    HOSPITAL FORMULARY, 1990, 25 (04): : 416 - 420
  • [50] The epidemiology of panic disorder and agoraphobia in Europe
    Goodwin, RD
    Faravelli, C
    Rosi, S
    Cosci, F
    Truglia, E
    de Graaf, R
    Wittchen, HU
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (04) : 435 - 443